From genotype to phenotype: The differential expression of FGF, FGFR, and TGFβ genes characterizes human cranioskeletal development and reflects clinical presentation in FGFR syndromes

Plastic and Reconstructive Surgery

Volumn 108, Issue 7, 2001, Pages 2026-2039

  Britto, J A ^a   Evans, R D ^a   Orth, M ^a   Hayward, R D ^a   Jones, B M ^a   Cohen M M , Jr ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE DEVELOPMENT; CARTILAGE CELL; CELL DIFFERENTIATION; CELL LINEAGE; CLINICAL FEATURE; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; EMBRYO; FIBROBLAST GROWTH FACTOR RECEPTOR SYNDROME; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OSSIFICATION; PHENOTYPE; PRIORITY JOURNAL; SKULL DEVELOPMENT;

EID: 0035661208     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006534-200112000-00030     Document Type: Article

References (95)

1. De l'acrocephalosyndactylic
2. Dominant erbliche akrocephalosyndaktylie
3. Dysostose cranio-faciale hereditaire
4. Differential expression of fibroblast growth factor receptors in human digital development suggests common pathogenesis in complex acrosyndactyly and craniosynostosis
5. Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus
6. Characteristics of the infant Apert skull and its subsequent development
7. Comparative three-dimensional analysis of CT-scans of the calvaria and cranial base in Apert and Crouzon syndromes
8. Cranial size and configuration in the Apert syndrome
9. Apert syndrome results from localized mutations of FGFR 2 and is allelic with Crouzon syndrome
10. Apertsyndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand
11. Craniosynostosis, midfacial hypoplasia and foot abnormalities: An autosomal dominant phenotype in a large Amish kindred
12. Chronic tonsillar herniation in Crouzon's and Apert's syndromes: The role of premature synostosis of the lambdoid suture
13. Fibroblast growth factor receptors: Lessons from the genes
14. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain
15. Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2
16. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras
17. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains
18. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome
19. Molecularly proven hypochondroplasia with cloverleaf skull deformity: A novel association
20. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia
21. Identification of a genetic cause for isolated unilateral coronal synostosis: A unique mutation in the fibroblast growth factor receptor 3
22. Prevalence of Pro 250Arg mutation of fibroblast growth factor receptor 3 in coronal craniosynostosis
23. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome
24. A common FGFR 3 gene mutation in hypochondroplasia
25. Craniosynostosis associated with FGFR 3 pro250arg mutation results in a range of clinical presentations including unisutural sporadic craniosynostosis
26. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3
27. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans
28. Achondroplasia is defined by recurrent G 380R mutations of FGFR3
29. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia
30. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia
31. Experimental unilateral coronal synostosis in rabbits
32. Expression of fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3) in the developing head and face
33. Pleiotropic features of syndromic craniosynostoses correlate with differential expression of fibroblast growth factor receptors 1 and 2 during human craniofacial development
34. Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification
35. Alterations in the expression of osteonectin, osteopontin and osteocalcin mRNAs during the development of skeletal tissues in vivo
36. Osteonectin: A differentiation marker of bone cells
37. Distribution of osteonectin mRNA and protein during human embryonic and fetal development
38. Restricted growth at the frontonasal suture: Alterations in craniofacial growth in rabbits
39. Craniofacial growth following experimental craniosynostosis and craniectomy in rabbits
40. The role of the cranial base in facial growth: Experimental craniofacial synostosis in the rabbit
41. Immunohistochemical localization of fibroblast growth factor receptors in the rat mandibular condylar cartilage and tibial cartilage
42. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis
43. Fibroblast growth factor receptor 3 is a negative regulator of bone growth
44. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3
45. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein
46. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3
47. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice
48. Fibroblast growth factor stimulates colony formation of differentiated chondrocytes in soft agar
49. Regulation of growth-plate chondrocytes by insulinlike growth-factor I and basic fibroblast growth factor
50. Inhibitory effects of basic fibroblast growth factor on chondrocyte differentiation
51. Fibroblast growth factor is an inhibitor of chondrocyte terminal differentiation
52. Reduction of basic fibroblasts growth factor receptor is coupled with terminal differentiation of chondrocytes
53. Fibroblast growth factor 2 control of vascular tone
54. Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice
55. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia
56. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II
57. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia
58. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I
59. Expression of FGFR 3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells
60. A neonatal lethal mutation in FGFR 3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos
61. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis
62. Repression of hedgehog signaling and BMP 4 expression in growth plate cartilage by fibroblast growth factor receptor 3
63. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice
64. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3
65. In vitro studies on clonal growth of chondrocytes in thanatophoric dysplasia
66. Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses
67. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation
68. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism
69. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia
70. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2)
71. Negative autoregulation of fibroblast growth factor 2 expression characterizing cranial development in cases of Apert (P253R mutation) and Pfeiffer (C278 F mutation) syndromes and suggesting a basis for differences in their cranial phenotypes
72. Determination of ligand binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene
73. Effect of fibroblast growth factors on outgrowth of facial mesenchyme
74. Epithelium is required for maintaining FGFR-2 expression levels in facial mesenchyme of the developing chick embryo
75. De novo alu-element insertions in FGFR 2 identify a distinct pathological basis for Apert syndrome
76. FGFR activation in skeletal disorders: Too much of a good thing
77. Craniosynostosis: Genes and mechanisms
78. Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome
79. Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders
80. Mutations causing achondroplasia and thanatophoric dysplasia alter bFGF-induced calcium signals in human diploid fibroblasts
81. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation
82. The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific
83. Opposite effects of recombinant human transforming growth factor-beta 1 on bone regeneration in vivo: Effects of exclusion of periosteal cells by microporous membrane
84. Role of active and latent transforming growth factor beta in bone formation
85. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats
86. Effects of transforming growth factor beta s and basic fibroblast growth factor on articular chondrocytes obtained from immobilized rabbit knees
87. Upregulated expression of fibroblast growth factor (FGF) receptors by transforming growth factor-beta1 (TGF-beta1) mediates enhanced mitogenic responses to FGFs in cultured human lung fibroblasts
88. Differential in vitro phenotype pattern, transforming growth factor-beta(1) activity and mRNA expression of transforming growth factor-beta(1) in Apert osteoblasts
89. Basic fibroblast growth factor and transforming growth factor beta-1 expression in the developing dura mater correlates with calvarial bone formation
90. TGF-beta s stimulate cell proliferation via an autocrine production of FGF-2 in corneal stromal fibroblasts
91. Transforming growth factor beta 1 stimulates the production of basic fibroblast growth factor binding proteoglycans in Balb/c3T3 cells
92. Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts
93. Cellular response to transforming growth factor-betal and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions